Skip to main content
. 2021 Aug 30;12:670862. doi: 10.3389/fphar.2021.670862

FIGURE 5.

FIGURE 5

Flowchart of the recommendations on how to handle DDIs for oral anticancer drugs metabolized by CYP3A if only clinical data from strong CYP3A inhibitors or inducers is available. Caution should be taken while using the flowchart for drugs in which auto-induction or -inhibition plays a role and drug-drug interaction studies are not performed on steady-state, or for drugs with nonlinear dose-exposure relationships.